Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women

Breast

Volumn 22, Issue 2, 2013, Pages 121-129

  Aydiner, Adnan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Adjuvant; Anastrozole; Breast; Exemestane; Letrozole

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; TAMOXIFEN;

BONE DISEASE; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; DRUG SAFETY; ENDOMETRIUM CANCER; EXTENDED THERAPY; FOLLOW UP; FRACTURE; HUMAN; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEQUENCED THERAPY; THROMBOEMBOLISM;

EID: 84875530244     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.01.014     Document Type: Review

References (30)

1. National Institute for Health and Clinical Excellence NICE technology appraisal guidance 112. Hormonal therapies for the adjuvant treatment of early estrogen receptor-positive breast cancer 2006, National Institute for Health and Clinical Excellence, UK, Available at:, [accessed 21.01.12]. http://guidance.nice.org.uk/TA112.
2. Nadji M., Gomez-Fernandez C., Ganjei-Azar P., Morales A. Immunohistochemistry of estrogen and progesterone receptors considered: experience with 5,993 breast cancers. Am J Clin Pathol 1998, 123:21-27.
3. Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998, 33:1609-1618.
4. Janni W., Hepp P. Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev 2010, 36(3):249-261.
5. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351:1451-1467. Early Breast Cancer Trialists' Collaborative Group.
6. Josefsson M.L., Leinster S.J. Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy. Breast 2010, 19(2):76-83.
7. Bria E., Ciccarese M., Giannarelli D., Cuppone F., Nisticò C., Nuzzo C., et al. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients. Cancer Treat Rev 2006, 32(5):325-332. [Epub 2006 Jun 12].
8. Van de Velde C.J., Verma S., van Nes J.G., Masterman C., Pritchard K.I. Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer. Cancer Treat Rev 2010, 36(1):54-62.
9. Dowsett M., Cuzick J., Ingle J., Coates A., Forbes J., Bliss J., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010, 28:509-518.
10. Coates A.S., Keshaviah A., Thürlimann B., Mouridsen H., Mauriac L., Forbes J.F., et al. Five years of letrozole compared with tamoxifene as initial adjuvant therapy for postmenopausal women with endocrine responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25:486-492.
11. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9(1):45-53. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group.
12. Coombes R.C., Kilburn L.S., Snowdon C.F., Paridaens R., Coleman R.E., Jones S.E., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369(9561):559-570.
13. Jakesz R., Jonat W., Gnant M., Mittlboeck M., Greil R., Tausch C., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366(9484):455-462.
14. Boccardo F., Rubagotti A., Guglielmini P., Fini A., Paladini G., Mesiti M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006, 17(Suppl. 7):vii10-vii14.
15. Mouridsen H., Giobbie-Hurder A., Goldhirsch A., Thürlimann B., Paridaens R., et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361(8):766-776. BIG 1-98 Collaborative Group.
16. Van de Verde C.J.H., Rea D., Seynaeve C., Putter H., Hasenburg A., Vannetzel J.M., et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomized phase 3 trial. Lancet 2011, 377:321-331.
17. Aihara T., Takatsuka Y., Ohsumi S., Aogi K., Hozumi Y., Imoto S., et al. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SASBC03 study. Breast Cancer Res Treat 2010, 121:379-387.
18. Cuzick J., Sestak I., Baum M., Buzdar A., Howell A., Dowsett M., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11(12):1135-1141.
19. Regan M.M., Neven P., Giobbie-Hurder A., Goldhirsch A., Ejlertsen B., Mauriac L., et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8•1 years median follow-up. Lancet Oncol 2011, 12(12):1101-1108.
20. Xu H.B., Liu Y.J., Li L. Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysis. Clin Breast Cancer 2011, 11(4):246-251.
21. Colleoni M., Giobbie-Hurder A., Regan M.M., Thürlimann B., Mouridsen H., Mauriac L., et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011, 29:1117-1124.
22. Kaufmann M., Jonat W., Hilfrich J., Eidtmann H., Gademann G., Zuna I., et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen. The ARNO 95 Study. J Clin Oncol 2007, 25:2664-2670.
23. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifene therapy for early stage breast cancer. N Engl J Med 2003, 349(19):1793-1802.
24. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005, 97(17):1262-1271.
25. Mamounas E.P., Jeong J.H., Wickerham D.L., Smith R.E., Ganz P.A., Land S.R., et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 2008, 26(12):1965-1971.
26. Jakesz R., Greil R., Gnant M., Schmid M., Kwasny W., Kubista E., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007, 99(24):1845-1853.
27. Jonat W., Gnant M., Boccardo F. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006, 7:991-996.
28. Lin N.U., Winer E.P. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 2008, 26:798-805.
29. Lønning P.E., Geisler J. Indications and limitations of third-generation aromatase inhibitors. Expert Opin Investig Drugs 2008, 17:723-739.
30. Study of anastrozole, letrozole, or exemestane with or without tamoxifen in treating postmenopausal women with hormone-responsive breast cancer that has been completely removed by surgery, NCT00541086. Available at: [accessed 21.01.12]. http://www.clinicaltrials.gov.